Effect of Telitacicept on Antibody Titers in Primary APS Patients

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

April 30, 2025

Study Completion Date

December 31, 2026

Conditions

Antiphospholipid Syndrome (APS)

Interventions

DRUG

Telitacicept+SOC

160mg once a week for 48 weeks

DRUG

SOC

SOC treatment includes aspirin and/or vitamin K antagonists (VKA) and/or low molecular weight heparin.

Trial Locations (1)

Ruijin Hospital, Shanghai

All Listed Sponsors

lead

Ruijin Hospital

OTHER

NCT06315530 - Effect of Telitacicept on Antibody Titers in Primary APS Patients | Biotech Hunter | Biotech Hunter